Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have revealed today that the COVID-19 vaccine candidate, BNT162b2, has shown encouraging results in the first interim analysis from the Phase III study. The independent Data Monitoring Committee (DMC) has reviewed the mRNA-based vaccine candidate